(Q37579650)

21 August 2017

1 reference

title

Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs (English)

1 reference

21 August 2017

1 reference

H A Burris

1

1 reference

PubMed ID

19680296

21 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

21 August 2017

1 reference

21 August 2017

28 Suppl 1

1 reference

21 August 2017

S4-13

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2009.196

21 August 2017

0 references

cites work

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

The Bcl-2 apoptotic switch in cancer development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

The epidermal growth factor receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Lung cancer--time to move on from chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Considerations for second-line therapy of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

The development of HKI-272 and related compounds for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.196

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.196

1 reference

21 August 2017

1 reference

PubMed ID

19680296